Tonix Pharmaceuticals Holding Corp.
TNXPStock
$11.85−73.73%52W
Market Cap$185.07M
P/E—
Div yield—
Beta1.70
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-35.18%
Price vs S&P 500 (4W)-0.77%
VGM Score53.98
Market Capitalization$185.07M
Earnings Surprise History
Q1 26-2.93est. -2.48
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.13
4.11
4.20
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TNXPTonix Pharmaceuticals Holding Corp. | — | A | D | $11.85 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Tonix Pharmaceuticals is a commercial-stage biotech company developing treatments for CNS disorders and immunological conditions. Its approved product TONMYA treats fibromyalgia, while marketed migraine medications Zembrace SymTouch and Tosymra provide current revenue. The company is expanding TONMYA into depression and acute stress disorder through clinical trials and advancing a pipeline including TNX-4800 for Lyme disease prevention and TNX-1500 for transplant rejection prevention.